Prospective study of sequential reduction in immunosuppression, interferon alpha-2b, and chemotherapy for posttransplantation lymphoproliferative disorder

被引:89
作者
Swinnen, Lode J. [1 ]
LeBlanc, Michael [2 ]
Grogan, Thomas M. [3 ]
Gordon, Leo I. [4 ]
Stiff, Patrick J. [5 ]
Miller, Alan M. [6 ]
Kasamon, Yvette [1 ]
Miller, Thomas P. [3 ]
Fisher, Richard I. [7 ]
机构
[1] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21231 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Univ Arizona, Ctr Canc, Tucson, AZ USA
[4] Northwestern Univ, Sch Med, Chicago, IL USA
[5] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA
[6] Tulane Canc Ctr, New Orleans, LA USA
[7] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY USA
关键词
PTLD; lymphoma; immunosuppressive reduction; S9239;
D O I
10.1097/TP.0b013e3181761659
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is Usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. Methods. Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for I week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m(2)/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. Results. Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR. Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection. Only I of 13 (7%) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years. Conclusions. Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to R1 as initial therapy. Chemotherapy resulted in 57% durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 20 条
[1]  
ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877
[2]   Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].
Benkerrou, M ;
Jais, JP ;
Leblond, V ;
Durandy, A ;
Sutton, L ;
Bordigoni, P ;
Garnier, JL ;
Le Bidois, J ;
Le Deist, F ;
Blanche, S ;
Fischer, A .
BLOOD, 1998, 92 (09) :3137-3147
[3]   Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study [J].
Choquet, S ;
Leblond, V ;
Herbrecht, R ;
Socié, G ;
Stoppa, AM ;
Vandenberghe, P ;
Fischer, A ;
Morschhauser, F ;
Salles, G ;
Feremans, W ;
Vilmer, E ;
Peraldi, MN ;
Lang, P ;
Lebranchu, Y ;
Oksenhendler, E ;
Garnier, JL ;
Lamy, T ;
Jaccard, A ;
Ferrant, A ;
Offner, F ;
Hermine, O ;
Moreau, A ;
Fafi-Kremer, S ;
Morand, P ;
Chatenoud, L ;
Berriot-Varoqueaux, N ;
Bergougnoux, L ;
Milpied, N .
BLOOD, 2006, 107 (08) :3053-3057
[4]  
Choquet S, 2003, BLOOD, V102, p49B
[5]   Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants [J].
Davis, CL ;
Wood, BL ;
Sabath, DE ;
Joseph, JS ;
Stehman-Breen, C ;
Broudy, VC .
TRANSPLANTATION, 1998, 66 (12) :1770-1779
[6]  
FISCHER A, 2001, NEW ENGL J MED, V324, P1451
[7]   Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases? [J].
Ghobrial, IM ;
Habermann, TM ;
Macon, WR ;
Ristow, KM ;
Larson, TS ;
Walker, RC ;
Ansell, SM ;
Gores, GJ ;
Stegall, MD ;
McGregor, CG .
TRANSPLANTATION, 2005, 79 (02) :244-247
[8]  
Ghobrial IM, 2003, BLOOD, V102, p392A
[9]   EPSTEIN-BARR VIRUS-INDUCED B-CELL LYMPHOMA AFTER RENAL-TRANSPLANTATION - ACYCLOVIR THERAPY AND TRANSITION FROM POLYCLONAL TO MONOCLONAL B-CELL PROLIFERATION [J].
HANTO, DW ;
FRIZZERA, G ;
GAJLPECZALSKA, KJ ;
SAKAMOTO, K ;
PURTILO, DT ;
BALFOUR, HH ;
SIMMONS, RL ;
NAJARIAN, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (15) :913-918
[10]   Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders [J].
Leblond, V ;
Dhedin, N ;
Bruneel, MFM ;
Choquet, S ;
Hermine, O ;
Porcher, R ;
Quoc, SN ;
Davi, F ;
Charlotte, F ;
Dorent, R ;
Barrou, B ;
Vernant, JP ;
Raphael, M ;
Levy, V .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :772-778